Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial

被引：1
|
作者：
Park, H. [1 ]
Sanjeevaiah, A. [2 ]
Suresh, R. [1 ]
Mehta, R. [3 ]
Trikalinos, N. [1 ]
Bagegni, N. [1 ]
Aranha, O. [1 ]
Pedersen, K. [1 ]
Nixon, A. [4 ]
Jin, R. [1 ]
Mills, J. [1 ]
Fields, R. [1 ]
Amin, M.
Lim, K.
Tan, B. [1 ]
Grierson, P. [1 ]
Jiang, S. [1 ]
del Rosario, M. [1 ]
Wang-Gillam, A. [1 ]
Lockhart, A. [5 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] UT Southwestern Med Ctr, Dallas, TX USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Duke Univ, Med Ctr, Durham, NC 27706 USA
[5] Univ Miami, Miller Sch Med, Sylvester Canc Ctr, Miami, FL 33136 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-131
引用
收藏
页码：S132 / S132
页数：1
相关论文
共 50 条
  • [31] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progress
    Catenacci, Daniel V. T.
    Strickler, John H.
    Nakamura, Yoshiaki
    Shitara, Kohei
    Janjigian, Yelena Y.
    Barzi, Afsaneh
    Bekaii-Saab, Tanios S.
    Lenz, Heinz-Josef
    Chung, Hyun Cheol Cheol
    Tabernero, Josep
    Yoshino, Takayuki
    Siena, Salvatore
    Mayor, Joal Garrido
    Palanca-Wessels, Maria Corinna
    Xie, Diqiong
    Marshall, John
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [32] Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
    Hironaga Satake
    Tamotsu Sagawa
    Koshi Fujikawa
    Yukimasa Hatachi
    Hisateru Yasui
    Masahito Kotaka
    Takeshi Kato
    Akihito Tsuji
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 839 - 845
  • [33] Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
    Satake, Hironaga
    Sagawa, Tamotsu
    Fujikawa, Koshi
    Hatachi, Yukimasa
    Yasui, Hisateru
    Kotaka, Masahito
    Kato, Takeshi
    Tsuji, Akihito
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (05) : 839 - 845
  • [34] A Phase 2 Trial of Erlotinib in Patients With Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus
    Ilson, David H.
    Kelsen, David
    Shah, Manish
    Schwartz, Gary
    Levine, Douglas A.
    Boyd, Jeff
    Capanu, Marinela
    Miron, Benjamin
    Klimstra, David
    CANCER, 2011, 117 (07) : 1409 - 1414
  • [35] A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)
    Ryohei Kawabata
    Naoki Izawa
    Takahisa Suzuki
    Yoshio Nagahisa
    Kazuhiro Nishikawa
    Masazumi Takahashi
    Masato Nakamura
    Atsushi Ishiguro
    Hiroo Katsuya
    Jun Hihara
    Dai Manaka
    Yuji Negoro
    Akihito Tsuji
    Takao Takahashi
    Mitsugu Kochi
    Mizutomo Azuma
    Shigenori Kadowaki
    Hirofumi Michimae
    Yu Sunakawa
    Wataru Ichikawa
    Masashi Fujii
    Targeted Oncology, 2023, 18 : 359 - 368
  • [36] A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)
    Kawabata, Ryohei
    Izawa, Naoki
    Suzuki, Takahisa
    Nagahisa, Yoshio
    Nishikawa, Kazuhiro
    Takahashi, Masazumi
    Nakamura, Masato
    Ishiguro, Atsushi
    Katsuya, Hiroo
    Hihara, Jun
    Manaka, Dai
    Negoro, Yuji
    Tsuji, Akihito
    Takahashi, Takao
    Kochi, Mitsugu
    Azuma, Mizutomo
    Kadowaki, Shigenori
    Michimae, Hirofumi
    Sunakawa, Yu
    Ichikawa, Wataru
    Fujii, Masashi
    TARGETED ONCOLOGY, 2023, 18 (03) : 359 - 368
  • [37] A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer
    Bando, Hideaki
    Shimodaira, Hideki
    Fujitani, Kazumasa
    Takashima, Atsuo
    Yamaguchi, Kensei
    Nakayama, Norisuke
    Takahashi, Takehiro
    Oki, Eiji
    Azuma, Mizutomo
    Nishina, Tomohiro
    Hironaka, Shuichi
    Komatsu, Yoshito
    Shitara, Kohei
    EUROPEAN JOURNAL OF CANCER, 2018, 91 : 86 - 91
  • [38] A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma
    Park, Haeseong
    Wang-Gillam, Andrea
    Suresh, Rama
    Rigden, Caron E.
    Amin, Manik A.
    Tan, Benjamin R.
    Pedersen, Katrina
    Lim, Kian-Huat
    Trikalinos, Nikolaos
    Navo, Katherine
    Morton, Ashley
    Schrumpf, Lindsey
    Marquez, Samantha
    Trinkaus, Kathryn
    Lockhart, A. Craig
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [39] Gemcitabine and irinotecan in patients with previously treated carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network phase II trial
    Doss, HH
    Hainsworth, JD
    Spigel, DR
    Kommor, M
    Zakem, M
    Raefsky, EL
    Litchy, S
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 355S - 355S
  • [40] Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction
    Sandler, AB
    Kindler, HL
    Einhorn, LH
    Mitchell, E
    Masters, G
    Kraut, M
    Nicol, S
    Raghavan, D
    ANNALS OF ONCOLOGY, 2000, 11 (09) : 1161 - 1164
12345